核心概念
Pharmacogenomic testing for antidepressants can significantly reduce the time and cost of finding effective medication for patients with major depressive disorder.
要約
The content discusses the impact of pharmacogenomic testing on antidepressant treatment for patients with major depressive disorder. It highlights the development of a microsimulation model to evaluate the effectiveness and cost-effectiveness of pharmacogenomic testing in British Columbia, Canada. The study predicts reduced development of refractory depression, increased time of patients feeling well, and substantial cost savings for the healthcare system over 20 years. The model also shows higher remission rates, lower discontinuation rates, and overall improved outcomes for patients undergoing pharmacogenomic-guided treatment.
統計
Testing could result in 37% fewer patients developing refractory depression.
Health system cost-savings of $956 million CAD over 20 years.
23,216 (37%) fewer patients developing refractory depression with pharmacogenomic-guided treatment.
$4926 CAD per patient saved with pharmacogenomic-guided treatment.
15% more time in the "well" state without depression symptoms for patients undergoing testing.
18% less time in the MDD state with recurrent episodes or refractory depression for tested patients.
.064 life-years and .381 quality-adjusted life-years (QALYs) gained per patient with testing.
引用
"Our study shows that if pharmacogenomic testing guides the prescription of an effective antidepressant, it can reduce the lengthy trial-and-error process many patients experience and dramatically reduce the financial burden on the healthcare system." - Shahzad Ghanbarian, PhD
"These findings provide a solid economic justification for clinical implementation of pharmacogenomic-guided depression treatment in Canada." - Chad Bousman, PhD